We are excited to announce the completion of a £6M financing round to accelerate the development of our novel antibody therapeutics.
2021 is going to be a fantastic year working with LifeArc, Sedgwick Yard, Oxford Sciences Innovation and Amgen Ventures LLC to discover and develop new treatments for patients with chronic inflammatory diseases.
